Glass House Brands (GLAS) Total Current Liabilities (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Total Current Liabilities of $40.2 million for Q1 2026, up 5.89% year-over-year from $38.0 million in Q1 2025, and up 5.92% quarter-over-quarter from $38.0 million in Q4 2025.
Glass House Brands (GLAS) Total Current Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Total Current Liabilities for 7 consecutive years, with $40.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 5.89% year-over-year to $40.2 million; the TTM figure through Mar 2026 stood at $40.2 million (up 5.89% YoY), while the FY2025 annual figure was $38.0 million, down 42.9% from the prior year.
- Total Current Liabilities improved to $40.2 million in Q1 2026 per GLAS's latest filing, from $38.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $97.0 million in Q1 2024 and bottomed at $33.2 million in Q3 2025.
- Historically, Total Current Liabilities has averaged $64.6 million across 5 years, with a median of $62.1 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 150.9% — and 2025, when it plunged 60.84%.
- Glass House Brands' Total Current Liabilities stood at $54.0 million in 2022, then jumped by 61.77% to $87.4 million in 2023, then retreated by 23.9% to $66.5 million in 2024, then tumbled by 42.9% to $38.0 million in 2025, then climbed by 5.92% to $40.2 million in 2026.
- Business Quant data shows GLAS's Total Current Liabilities at $40.2 million in Q1 2026, $38.0 million in Q4 2025, and $33.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.79 Bn |
| 10 | Glass House Brands | 830.21 Mn | 811.66 Mn | 15.77 Mn | 53.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.21 Mn |
| Dec 31, 2025 | 37.96 Mn |
| Sep 30, 2025 | 33.23 Mn |
| Jun 30, 2025 | 43.37 Mn |
| Mar 31, 2025 | 37.97 Mn |
| Dec 31, 2024 | 66.48 Mn |
| Sep 30, 2024 | 82.22 Mn |
| Jun 30, 2024 | 89.91 Mn |
| Mar 31, 2024 | 96.96 Mn |
| Dec 31, 2023 | 87.36 Mn |
| Sep 30, 2023 | 87.55 Mn |
| Jun 30, 2023 | 85.63 Mn |
| Mar 31, 2023 | 62.13 Mn |
| Dec 31, 2022 | 54.00 Mn |
| Sep 30, 2022 | 56.49 Mn |
| Jun 30, 2022 | 75.85 Mn |
| Mar 31, 2022 | 60.79 Mn |
| Dec 31, 2021 | 55.24 Mn |
| Sep 30, 2021 | 60.28 Mn |
| Jun 30, 2021 | 30.23 Mn |